Replimune Group

Replimune Group

Replimune was founded in 2015 by Robert Coffin and Philip Astley-Sparke, two veterans of BioVex, the company that developed talimogene laherparepvec (T-VEC), the first and only FDA-approved oncolytic virus therapy. Coffin invented T-VEC. Astley-Sparke led BioVex's US operations until Amgen acquired the firm in 2011 for up to $1 billion. Replimune launched with a $30 million Series A in 2016, followed by a $55 million Series B in 2017, and went public on Nasdaq in July 2018, raising $100 million. The company operates a manufacturing facility in Oxford, UK, and a research and clinical headquarters in Woburn, Massachusetts. The firm's platform centers on a proprietary strain of herpes simplex virus engineered to kill cancer cells directly and produce immune-stimulating proteins within the tumor microenvironment. The pipeline spans three clinical-stage candidates. RP1 is in a registrational Phase 3 trial for advanced melanoma in combination with Regeneron's PD-1 inhibitor Libtayo. RP2 targets liver, gastrointestinal, and head-and-neck cancers, with Phase 2 data presented at the 2024 American Society of Clinical Oncology conference showing durable responses in uveal melanoma — a historically difficult-to-treat indication lacking standard immunotherapy options. RP3 is designed for melanoma and cervical cancer, incorporating additional genes to amplify T-cell priming. The US-UK dual structure gives Replimune direct GMP manufacturing capability, a rarity among clinical-stage biotechs of its size. As of its March 2025 full-year filing, Replimune employed approximately 135 people across its Massachusetts and Oxford locations. The company reported $126.5 million in cash, which management projected to fund operations into the second half of 2026. In October 2024, the company received breakthrough therapy designation from the FDA for RP1 in combination with Libtayo for advanced melanoma, a regulatory milestone that typically accelerates review timelines. Replimune has not spun out a separate foundation or adjacent vehicle, and remains tightly focused on developing its clinical pipeline toward commercialization. Replimune's structural distinction lies in its direct engineering of the viral backbone rather than relying on external platforms or in-licensed vectors. The company controls its own manufacturing, its own clinical trials, and the intellectual property derived from Coffin's original T-VEC work at BioVex. In a biotech landscape where most oncolytic virus companies have failed to advance past early-phase studies, the Phase 3 registrational trial and the 2024 breakthrough designation position Replimune as one of the few independent firms with a shot at fielding a new class of approved cancer therapy.